Cagrilintide
Also known as: AM833, Cagrilintide acetate, CagriSema, OZM002
Source Cagrilintide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Cagrilintide is a long‑acting synthetic amylin analogue under development for obesity and type 2 diabetes. It is administered subcutaneously and has shown clinically meaningful weight loss and modest HbA1c reductions in Phase 2 trials.
Mechanism of Action
Agonist at amylin (calcitonin) receptors, reducing appetite, slowing gastric emptying, and improving glycemic control.
Routes of Administration
Goals & Uses
- Weight loss / anti-obesityMetabolicModerate
- Cardiovascular risk reductionCardiovascularLow
- Weight lossMetabolicModerateChronic weight management and appetite reduction
- Appetite suppressionMetabolicModerate
- Gastric emptying modulationGastrointestinalModerate
- Glycemic controlDiabetesModerate
- Glycemic control in type 2 diabetesMetabolicModerate
Contraindications
- Personal or family history of medullary thyroid carcinomaOncologicHigh
- Multiple endocrine neoplasia syndrome type 2 (MEN2)OncologicHigh
- Hypersensitivity to cagrilintide or excipientsImmunologicHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Medullary thyroid carcinomaOncologyModerate
- Hypersensitivity to amylin analoguesAllergyHigh
Adverse Effects
- HypoglycemiaMetabolicUncommonAbnormally low blood glucose
- Injection site reactionsLocalUncommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Decreased appetiteMetabolicCommonReduced desire to eat
- DiarrheaGastrointestinalCommonLoose or frequent stools
- Injection‑site reactionLocalCommon
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- Oral medications with narrow therapeutic indexModerate
- SulfonylureasModerateMay increase risk of low blood sugar
- SemaglutideLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pediatric (<18 y)AgeAbsolute
- Pregnant or breastfeeding womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalUnder EMA review; no marketing authorization.
- United StatesInvestigationalPhase 2/3 trials ongoing; not FDA‑approved.
- United KingdomInvestigationalNo approval; clinical trial participation ongoing.
Not approved in any jurisdiction; currently in Phase 2/3 clinical development.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Cagrilintide?
Cagrilintide is a long‑acting synthetic amylin analogue under development for obesity and type 2 diabetes. It is administered subcutaneously and has shown clinically meaningful weight loss and modest HbA1c reductions in Phase 2 trials.
What is Cagrilintide used for?
Cagrilintide is educationally associated with: Weight loss / anti-obesity, Cardiovascular risk reduction, Weight loss, Appetite suppression, Gastric emptying modulation, Glycemic control, Glycemic control in type 2 diabetes. Educational only — not medical advice.
How is Cagrilintide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Cagrilintide?
Reported adverse effects include: Hypoglycemia, Injection site reactions, Headache, Nausea, Vomiting, Decreased appetite, Diarrhea, Injection‑site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Cagrilintide?
Recorded contraindications: Personal or family history of medullary thyroid carcinoma, Multiple endocrine neoplasia syndrome type 2 (MEN2), Hypersensitivity to cagrilintide or excipients, Pregnancy, Medullary thyroid carcinoma, Hypersensitivity to amylin analogues. Consult a qualified clinician before use.